Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Must Codify Flexibility For Rare Diseases, Coté Says As He Moves To NORD

Executive Summary

FDA needs to formalize the flexibility it has employed in its rare disease program, according to Tim Coté, the National Organization for Rare Disorders’ new Chief Medical Officer and former head of the agency’s orphan products development program.

You may also be interested in...

FDA Orphan Drug Reviewers Should Seek Help From NIH, Genzyme Says

CEO Meeker suggests a program where NIH scientists have a rotation at FDA where they take part in drug reviews for an extended period, instead of only for a short time as a consultant.

Good Neighbors Make Good Regulatory Science Centers, FDA Decides

Georgetown, Maryland gain CERSI grants in part because of their proximity to agency staff.

PDUFA Commitment Letter Formalizes REMS Standardization Schedule

Among other timetables set as part of the broad deal with industry, FDA will host meetings and issue guidances to assess and minimize the burden of REMS on the practitioners and patients.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts